|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.320 USD | +0.87% |
|
+4.50% | +28.89% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 186.9 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 29.13% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 186.9 | 186.9 | 186.9 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 29.13% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 11.9x | 46.4x | 232x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.6x | -2.9x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.39x | 2.77x | 2.77x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.39x | 2.77x | 2.77x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 10.7x | 63x | 757x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.195 | 0.05 | 0.01 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 78.3 | 67.56 | 67.46 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 17.52 | 2.968 | 0.247 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 15.72 | 4.074 | 0.731 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.320 | 2.320 | 2.320 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 3/31/22 | 2/27/23 | 3/14/24 | 3/17/25 | 3/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 11.9x | - | - | - | 187M | |
| 35.49x | 12.89x | 26.26x | 0.56% | 1,082B | |
| 28.11x | 6.46x | 17.57x | 2.03% | 633B | |
| 32.2x | 7.69x | 15.73x | 2.65% | 461B | |
| 18.2x | 4.52x | 11.11x | 2.93% | 339B | |
| 24.21x | 5.06x | 14.18x | 1.72% | 301B | |
| 22.23x | 5.7x | 13.76x | 2.76% | 292B | |
| 14.65x | 5.43x | 11.14x | 3.42% | 225B | |
| 24.39x | 6.45x | 11.36x | 2.7% | 202B | |
| -46.87x | 5.66x | 31.47x | 2.47% | 163B | |
| Average | 16.45x | 6.65x | 16.95x | 2.36% | 369.99B | |
| Weighted average by Cap. | 24.76x | 8.04x | 18.59x | 1.93% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
